Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2020.06.01

Ensuring manufacturing continuity during the pandemic

Ensuring manufacturing continuity during the pandemic. Together.

‘Make it better together’ is a guiding tenet for how we operate each day. Yet, as it often does during a crisis, a truly collaborative effort during the present pandemic involving all our supply partners, airline & shipping companies, freight forwarders, transporters and our own cross-functional teams, has emphatically reinforced this belief. It has allowed us to keep our supply chain intact ensuring that our manufacturing operations continued with zero downtime and enabled us to uphold our commitments to our customers.

Proactive risk identification
Anticipating the supply chain risk well before COVID-19 was declared a global pandemic, we conducted a survey covering all our partners, especially in the affected countries, to assess the risk and get a granular understanding of the extent of supply impact across various projects. This timely and detailed information helped our supply chain team develop various strategies to mitigate or minimize the impact.

Translating plans to actions
For an intense period of close to ten weeks, all our cross-functional teams and external partners sustained a 24 x 7 operating model spanning various time zones and implementing solutions in real-time. The team shifted all pending orders in highly affected zones to partners located in medium and low impact zones, by leveraging the strong relationships built over time. We also increased the share of supplies from partners located in less impacted regions. Once the materials were ready, their movement posed a considerable challenge. The team had to reroute several shipments adopting complex logistics solutions involving multi-mode, multi-continent and multi 3PL operators. We used all functional entry gateways, both airports and seaports, which were functional for both inbound and outbound shipments.

Gratifying outcome of collaborative effort
The team handled a total of 294 shipments from the start of lockdown, honouring the delivery commitment to the customers with OTIF > 97% while ensuring zero downtime in the manufacturing activity. Most importantly, the entire effort demonstrated the strength and resilience of our relationships, and an unwavering zeal to make it better together.

Share article

More News

2025.11.27

India is evolving from being a tactical supplier to a strategic partner to global pharma

Krishna Kanumuri, MD & CEO of Sai Life Sciences, was recently interviewed by Pharmaceutical Executive for its feature on next-generation CDMOs. In the interview, he shares insights on how Indian CDMOs are evolving from tactical suppliers to strategic partners, the shifting global supply-chain landscape, and how Sai Life Sciences is preparing for the opportunities and […]
Read more

2025.11.27

Decoding the Signals of Life: CDFD’s Dr. Rashna Bhandari visits Sai

Dr. Rashna Bhandari, Principal Investigator at the Centre for DNA Fingerprinting and Diagnostics (CDFD), Hyderabad, recently visited our Sai Life Sciences campus to deliver an insightful masterclass on “Phosphate-rich biomolecules in cell signalling.” In her session, Dr. Bhandari explored how phosphate-rich molecules act as vital messengers that regulate cellular communication and coordination. She explained how […]
Read more

2025.11.08

SLSC_Sankalp

Sai Life Sciences Launches Child Safety Awareness Program in Government Schools in Hyderabad with Sankalp

Raising awareness around child safety requires sensitivity and a collective effort to help children recognize unsafe situations and know how to respond. Guided by this purpose, Sai Life Sciences, in partnership with Sankalp NGO, has launched a Child Sexual Abuse Prevention Program across ten government schools in Gachibowli, Hyderabad. The program features two age-appropriate curriculums […]
Read more

2025.11.07

Sai Life Sciences Limited

Sai Life Sciences Limited sustains growth momentum in Q2FY26

Revenue up by 36%; EBITDA up by 43%; Net Profit up by 100% Hyderabad, November 06, 2025: Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), one of India’s fastest growing Contract Research, Development and Manufacturing Organizations (CRDMO) announced its financial results for the second quarter and half year ended September 2025. Financial Performance: Particulars […]
Read more

2025.11.05

Where Nature Inspires Innovation: University of Kansas Prof. Apurba Dutta visits Sai

Dr. Apurba Dutta, Associate Professor at Department of Medicinal Chemistry, University of Kansas, USA, recently visited our Sai Life Sciences campus to deliver a masterclass on “A serine-derived second-generation chiron: Applications in the synthesis of natural and nature-like molecular scaffolds.”During the session, he explored how simple natural molecules can serve as versatile building blocks for […]
Read more